Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial
Sign Up to like & getrecommendations! Published in 2023 at "Respirology"
DOI: 10.1111/resp.14452
Abstract: In the INBUILD trial in patients with progressive fibrosing interstitial lung diseases (ILDs), nintedanib reduced the rate of decline in forced vital capacity (FVC) with an adverse event profile characterized mainly by gastrointestinal events. We… read more here.
Keywords: fibrosing interstitial; progressive fibrosing; lung diseases; inbuild trial ... See more keywords
OP0124 EFFECTS OF NINTEDANIB IN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE ASSOCIATED WITH RHEUMATOID ARTHRITIS (RA-ILD) IN THE INBUILD TRIAL
Sign Up to like & getrecommendations! Published in 2021 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2021-eular.969
Abstract: Background: In the INBUILD trial in subjects with progressive fibrosing ILDs other than idiopathic pulmonary fibrosis (IPF), nintedanib reduced the rate of decline in FVC (mL/year) over 52 weeks by 57% compared with placebo. Objectives:… read more here.
Keywords: boehringer ingelheim; trial; group; inbuild trial ... See more keywords
Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
Sign Up to like & getrecommendations! Published in 2022 at "Respiratory Research"
DOI: 10.1186/s12931-022-01974-2
Abstract: Background In the INBUILD trial in patients with progressive fibrosing interstitial lung diseases (ILDs), nintedanib reduced the rate of decline in forced vital capacity compared with placebo, with side-effects that were manageable for most patients.… read more here.
Keywords: adverse events; progressive fibrosing; inbuild trial; patients progressive ... See more keywords